Sanofi Bolsters Immunology Portfolio with US$1.45 B Kymab Acquisition
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 1 (Table of Contents)
Published: 19 Jan-2021
DOI: 10.3833/pdr.v2021.i1.2585 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Continuing its M&A deal spree, Sanofi has agreed to acquire Kymab, a clinical-stage company developing antibody therapies for immune-mediated diseases and immuno-oncology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS